Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Med Arh ; 62(3): 175-6, 2008.
Article in Bosnian | MEDLINE | ID: mdl-18822950

ABSTRACT

Chronic lymphatic leukemia (CLL) is the most frequent type of leukemia in western world, and a choice of treatment modality depends on current stage of disease. Clinical condition of patient considered as Binnet C stage, requires treatment. Standard polyhemiotherapy (FC protocol) does not always warrant adequate and satisfactory response. This case report reviews the patient with CLL in Binnet C stage, who did not respond on FC protocol in expected way, meaning, hematological and medullar response was not detected. Twelve weeks therapy of monoclonal antiCD52 antibody (MabCampath) was than applied, resulting in normalization of all parameters of disease activity, which was desired effect of the therapy. Administration of monoclonal antiCD52 antibody is justified in case of resistance on conventional previously applied means of therapy.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antibodies, Neoplasm/therapeutic use , Antineoplastic Agents/therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Adult , Alemtuzumab , Antibodies, Monoclonal, Humanized , Antigens, CD/immunology , Antigens, Neoplasm/immunology , CD52 Antigen , Glycoproteins/immunology , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...